Navigation Links
Lyncean Technologies Inc. sells Compact Light Source to Munich biomedical-imaging research center
Date:12/13/2012

Palo Alto-based Lyncean Technologies, Inc., today announced its first sale of a Compact Light Source, a miniature synchrotron X-ray source employing state-of-the-art laser-beam and electron-beam technology.

A Lyncean "Compact Light Source" (CLS) was purchased by researchers from the newly-formed Center for Advanced Laser Applications (CALA) in Germany, a joint project of the Ludwig Maximilians University of Munich (LMU) and the Technical University Munich (TUM). The device will be fully built and tested in Lyncean's facility in Palo Alto, Calif. and delivered to Munich in early 2014.

"Today is a milestone for us," said Ronald Ruth, Lyncean's founder and Chairman of the Board. "We feel we have an innovative tool, especially as X-rays are playing a growing role in areas like structural biology, medical science, nanotech and fuel cell research. We've been fortunate to have had so much support developing the technology, but putting a CLS in the hands of scientists has always been the ultimate goal."

With its first sale to a team of researchers, Lyncean expects a growing demand by scientists and students at the forefront of biomedical X-ray imaging research. Prof. Franz Pfeiffer, Chair for Biomedical Physics at TUM, leads a group of X-ray scientists pioneering new imaging techniques that reveal striking details in soft tissue that have been difficult to detect using conventional methods. He's eager to see the new X-ray source put to use.

"The field of X-ray imaging is evolving rapidly, and with this novel source, we are adding a powerful tool to our facility," Dr. Pfeiffer said. "I expect having our own CLS here in Munich will significantly boost the research projects in our excellence cluster Munich-Centre for Advanced Photonics (MAP)."

Lyncean has been collaborating with Dr. Pfeiffer's group informally since 2007, when an impromptu visit one afternoon led to an experiment and later publication that was featured on the cover of the Journal of Synchrotron Radiation in January 2009, [doi:10.1107/S090904950803464X]. Subsequent experiments using the CLS prototype operating at Lyncean have produced a variety of joint publications, primarily with a medical emphasis, highlighting the machine's ability to improve tumor detection and early diagnosis of lung disease (a study that was just published in the Proceedings of the National Academy of Sciences [doi: 10.1073/pnas.1206684109]).

"Because the CLS is a new breed of X-ray source, with unique properties, we work with X-ray scientists to understand their applications," Dr. Ruth said. "The TUM collaboration is a good example of how we can successfully adapt our source for a particular application, in this case biomedical imaging."

The US National Institutes of Health provided funding for CLS development in order to help address the growing demand of life-science users who rely on synchrotrons for structural biology research. In addition to the CLS, Lyncean has also developed X-ray applications such as protein crystallography and power diffraction using focused beams from special X-ray optics. Researchers, though, use a wide variety of experimental techniques when applying synchrotron radiation to their own problems. The CLS, like a large synchrotron facility, is designed to perform a breadth of X-ray applications spanning fields from biology and chemistry to nanotechnology and materials science.


'/>"/>

Contact: Rod Loewen
rod_loewen@lynceantech.com
650-320-8300 x405
Lyncean Technologies, Inc.
Source:Eurekalert  

Related biology news :

1. NREL researchers use imaging technologies to solve puzzle of plant architecture
2. New energy technologies promise brighter future
3. Cross Match Technologies Undoubtedly Offers the Highest Value to Customers in the North American Biometrics Market, Says Frost & Sullivan
4. Life Technologies to supply new Covaris DNA fragmenting products for Ion Torrent Semiconductor Sequencers
5. ONR lines up speakers and technologies for 2012 Naval Conference
6. New NIH/NHGRI grants to harness nanoscale technologies to cut DNA sequencing costs
7. ASU awarded $3 million to research solar energy technologies, launch energy Ph.D. program
8. DNA Sequencing: Emerging Technologies and Applications
9. NHS set to benefit from UK-led technologies
10. New technologies for a blue future
11. Global Information Inc. Announces Discounted Conference Registration For Bio-IT World Asia and Biodetection Technologies 2012
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Lyncean Technologies Inc. sells Compact Light Source to Munich biomedical-imaging research center
(Date:12/16/2016)... , Dec 16, 2016 Research and Markets ... Market - Global Forecast to 2021" report to their offering. ... The biometric ... grow at a CAGR of 14.06% from 2016 to 2021. The ... is projected to reach 854.8 Million by 2021. The growth of ...
(Date:12/15/2016)... ... and Markets has announced the addition of the "Global Military Biometrics ... forecasts the global military biometrics market to grow at a CAGR of ... prepared based on an in-depth market analysis with inputs from industry experts. ... coming years. The report also includes a discussion of the key vendors ...
(Date:12/12/2016)... 12, 2016  Researchers at Trinity College, Dublin, ... by combining the material with Silly Putty. The mixture ... detector able to sense pulse, blood pressure, respiration, ... The research team,s findings were ... here:  http://science.sciencemag.org/content/354/6317/1257 ...
Breaking Biology News(10 mins):
(Date:1/19/2017)... GAITHERSBURG, Md. , Jan. 19, 2017 ... Inc., a privately-held immunotherapeutics company targeting infectious diseases, ... for the merger of PharmAthene and Altimmune in ... Venture Fund, HealthCap, Truffle Capital and Redmont Capital. ... diversified immunotherapeutics company with four clinical stage and ...
(Date:1/19/2017)... ... January 18, 2017 , ... ... innovators, engineers, and scientists from around the world, was today awarded the "Best ... program is based entirely on merit and decided upon by a dedicated team ...
(Date:1/19/2017)... Jan. 18, 2017  Northwest Biotherapeutics, Inc. (OTCQB: NWBO) ... immune therapies for operable and inoperable solid tumor cancers, ... Technical Officer of NW Bio, will present at the ... at the Hyatt Regency Hotel in Miami, ... the session entitled "New Therapeutic Approaches – Expanding the ...
(Date:1/18/2017)... According to a new market research report "In situ Hybridization Market ... User (Molecular Diagnostic Laboratories, Academic and Research Institutions) - Global Forecast to 2021" ... 2021 from USD 557.1 Million in 2016, growing at a CAGR of 5.8%. ... ... MarketsandMarkets Logo ...
Breaking Biology Technology: